CD22 and neoplasm: Preclinical studies of inotuzumab ozogamicin showed up to 39-fold more potent induction of in vitro tumor cell death compared to unconjugated calicheamicin in CD22+ B cell lymphoma cells [142] and significant in vivo tumor regression in lymphoma models as a single agent and in combination with rituximab, cyclophosphamide, vincristine, and prednisone (CVP), or CHOP [141, 142].